ARIA : Analysis & Opinions

  1. Ariad Leukemia Drug Gets Full US Approval (ARIA)

    November 30, 2016
    The FDA approval for the expanded use of Iclusig will increase its patient base, adding to higher drug sales.
  2. Ariad Pharma 3Q Loss 14c/Share vs 29 Cents (ARIA)

    November 8, 2016
    Aria Pharmaceutials reported a 3Q loss of 14 cents a share, above analyst projections.
  3. Pharma Stocks Prone to Decline From Democratic Win (MYL, ARIA)

    October 17, 2016
    Amid the political bashing of price raises by drug manufacturers, here are the stocks most prone to declines.
  4. Ariad Reports Positive Data for Cancer Drug (ARIA)

    October 12, 2016
    Ariad Pharmaceuticals said a mid-stage study of its cancer drug brigatinib for advanced non-small cell lung cancer shows ...
  5. Ariad Continues Iclusig Price Hike (ARIA)

    October 10, 2016
    While public criticism continues against increasing drug prices, Ariad has raised Iclusig’s price six times since early 2 ...
  6. Ariad Hits 52-Week High on Japan Approval (ARIA)

    September 29, 2016
    Along with commercial opportunities, Ariad also will benefit from payments from its partner
  7. Ariad Receives Interest as a Buyout Candidate

    September 22, 2016
    Following failed buyout talks with Baxalta last year, Ariad’s stock is spiking amid rumors of a takeover.
  8. Biotech Stocks: Are They Back?

    June 1, 2016
    The bearish trends over the past year have started to reverse themselves which has benefted the biotech industry
  9. Is Ariad Pharmaceuticals a Buyout Candidate?

    May 29, 2015
    It's amazing what a difference two years can make. Two years ago, Ariad Pharmaceuticals (NASDAQ: ARIA) was flying high on ...
  10. 3 Risks Ariad Investors Ought to Know About

    April 3, 2015
    Ariad Pharmaceuticals (NASDAQ: ARIA) already has one FDA-approved drug on the market, but that doesn't mean it's immune ...
  11. This Biotech Stock Gained 350%. Here's Why There's Still 86% ...

    February 10, 2014
    What a way to start 2014! Gloom and doom have struck the stock market with a roughly 1,000-point decline in the Dow Jones ...
Trading Center